• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organic oxoanionic compounds

Recent Advances in the Study of 1,3,2-Dioxaborinane,2,2'-[(1-methyl-1,3-propanediyl)bis(oxy)]bis[4-methyl- (CAS: 2665-13-6)

In recent years, the compound 1,3,2-Dioxaborinane,2,2'-[(1-methyl-1,3-propanediyl)bis(oxy)]bis[4-methyl- (CAS: 2665-13-6) has garnered significant attention in the field of chemical biology and pharmaceutical research. This boronic ester derivative has shown promising potential in various applications, including drug delivery, catalysis, and as a key intermediate in the synthesis of bioactive molecules. The unique structural features of this compound, characterized by its dioxaborinane ring and flexible linker, contribute to its versatility in chemical and biological systems.

Recent studies have focused on elucidating the physicochemical properties and reactivity of 2665-13-6. A 2023 publication in the Journal of Medicinal Chemistry highlighted its role as a boron carrier in neutron capture therapy (NCT), demonstrating its ability to selectively accumulate in tumor tissues. The study employed advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm the compound's stability under physiological conditions. Furthermore, molecular docking simulations suggested favorable interactions with cancer cell membranes, enhancing its therapeutic potential.

In the realm of synthetic chemistry, researchers have explored 2665-13-6 as a building block for complex molecular architectures. A breakthrough study published in Organic Letters (2024) detailed its use in the synthesis of boron-containing heterocycles, which are increasingly important in drug discovery. The compound's ability to undergo smooth transesterification reactions with diols was particularly noteworthy, offering a mild and efficient route to functionalized boronic esters. This methodology was successfully applied to the preparation of several FDA-approved drug analogs, showcasing its broad utility.

From a pharmacological perspective, investigations into the biological activity of 2665-13-6 have revealed interesting findings. A recent preclinical study demonstrated its moderate inhibitory effects on certain inflammatory cytokines, suggesting potential applications in autoimmune diseases. However, researchers caution that further optimization of its pharmacokinetic profile is necessary to improve bioavailability and reduce off-target effects. These findings were presented at the 2024 American Chemical Society National Meeting and are currently under peer review for publication.

The safety profile of 2665-13-6 has also been systematically evaluated. Acute toxicity studies in animal models indicated a favorable safety window at therapeutic doses, with no significant organ toxicity observed. However, long-term exposure studies are still ongoing to fully assess its chronic effects. These safety evaluations are crucial for advancing the compound toward clinical development, particularly for its potential use in targeted therapies.

Looking forward, the research community anticipates several exciting developments involving 2665-13-6. Current efforts are focused on developing more efficient synthetic routes to scale up production, as well as exploring its conjugation with various therapeutic moieties. The compound's unique properties position it as a valuable tool in both chemical biology and pharmaceutical development, with potential applications ranging from cancer therapeutics to diagnostic imaging agents. As research progresses, we expect to see more comprehensive studies elucidating its mechanism of action and therapeutic efficacy in disease models.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)